4552.Tライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (26 4月 2024 @ 15:15):

Stats
本日の出来高	800 300
平均出来高	720 063
時価総額	99.47B
EPS	¥0 ( 2024-01-25 )
次の収益日	( ¥16.69 ) 2024-05-08
Last Dividend	¥10.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	18.62
ATR14	¥0.642 (0.08%)

ボリューム相関

長: -0.14 (neutral)

短: 0.13 (neutral)

Signal:(54.951) Neutral

JCR Pharmaceuticals Co., 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

JCR Pharmaceuticals Co., 相関 - 通貨/商品

-0.36
( neutral )

-0.33
( neutral )

-0.31
( neutral )

-0.24
( neutral )

-0.10
( neutral )

0.32
( neutral )

JCR Pharmaceuticals Co., 財務諸表

Annual	2022
収益:	¥34.34B
総利益:	¥25.46B (74.13 %)
EPS:	¥30.34

FY	2022
収益:	¥34.34B
総利益:	¥25.46B (74.13 %)
EPS:	¥30.34

FY	2022
収益:	¥51.08B
総利益:	¥40.62B (79.52 %)
EPS:	¥117.26

FY	2021
収益:	¥30.09B
総利益:	¥22.27B (74.03 %)
EPS:	¥55.81

Financial Reports:

No articles found.

JCR Pharmaceuticals Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥10.00 (N/A)	¥0 (N/A)	¥10.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

JCR Pharmaceuticals Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.40 - Stable (12.03%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥1.250	2007-09-25
Last Dividend	¥10.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	30	--
Total Paid Out	¥100.88	--
Avg. Dividend % Per Year	0.00%	--
Score	3.56	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.40
Div. Directional Score	7.52	--

Next Divdend (Est)
(2024-09-30)

¥0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.56

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
4284.T	Ex Dividend Junior	2023-12-28	Annually	0.00%
3466.T	Ex Dividend Junior	2023-08-30	Semi-Annually	0.00%
2664.T	Ex Dividend Junior	2024-03-14	Annually	0.00%
9531.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8131.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
7476.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6702.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6037.T	Ex Dividend Junior	2024-07-30	Sporadic	0.00%
4725.T	Ex Dividend Knight	2023-12-28	Semi-Annually	0.00%
3965.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.130	1.500	7.41	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0522	1.200	8.26	9.91	[0 - 0.3]
returnOnEquityTTM	0.0987	1.500	-0.0142	-0.0213	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.801	0.800	6.00	4.80	[1 - 3]
quickRatioTTM	1.084	0.800	8.33	6.67	[0.8 - 2.5]
cashRatioTTM	0.573	1.500	7.93	10.00	[0.2 - 2]
debtRatioTTM	0.227	-1.500	6.22	-9.33	[0 - 0.6]
interestCoverageTTM	105.82	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	45.13	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	45.13	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.419	-1.500	8.33	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.748	1.000	0.861	0.861	[0.2 - 0.8]
operatingProfitMarginTTM	0.189	1.000	8.21	8.21	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.242	1.000	9.77	9.77	[0.2 - 2]
assetTurnoverTTM	0.402	0.800	-0.650	-0.520	[0.5 - 2]
Total Score				10.65

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	18.54	1.000	8.23	0	[1 - 100]
returnOnEquityTTM	0.0987	2.50	-0.00912	-0.0213	[0.1 - 1.5]
freeCashFlowPerShareTTM	45.13	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.51	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	45.13	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.168	1.500	-2.21	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.136	1.000	9.10	0	[0.1 - 0.5]
Total Score				4.40

JCR Pharmaceuticals Co.,

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.